Bayer extends research agreement with Hopkins through 2024
The pharmaceuticals and life sciences company will continue its partnership with Johns Hopkins to provide funding to researchers in the Wilmer Eye Institute
Credit: Wikimedia Commons
May 6, 2021
The Johns Hopkins University and Bayer AG have extended their strategic research alliance in ophthalmology through the end of 2024. The agreement will provide multimillion-dollar funding for researchers at the Johns Hopkins Wilmer Eye Institute to pursue treatments for a variety of eye diseases and ailments while benefitting from the expertise of Bayer scientists about potential drug candidates.
A drug candidate from one of the collaboration's programs has advanced to a phase II clinical trial and another program is licensed to a startup company. Researchers on both sides hope to translate the joint research into improved vision by moving innovative treatments from labs to patients' eyes.